Recent Developments in Ocular Nanotherapy: An Editorial
Abstract
Glaucoma is the second most leading cause of blindness [6]. It is a progressive optic neuropathy and has been commonly associated with elevated intraocular pressure (IOP) [7]. The conventional drug delivery system for treatment of glaucoma comprises of ocular drops and has been linked with numerous disadvantages such as natural anatomical barrier (low residence time), poor patient compliance, and local and systemic side effects [8]. Several sustained release drug delivery systems for anti-glaucoma drugs have been proposed that include intraocular implants [9], ophthalmic inserts [10], nano-and microparticles [11], liposomes [12], nanoemulsions [13], and contact lenses [14]. However, due to potential benefits of nanoparticles (NPs) over other delivery systems, further research is focused on finding new drugs and developing better nanoformulations. One such study introduced latanoprost (an ester prodrug of prostaglandin F2a with an efficiency to lower the IOP). Latanoprost acid (LA) is the pharmacologically active component of latanoprost. LA was entrapped in biocompatible and biodegradable nanoparticles formed using polylactide-poly(ethylene glycol) (PLA-PEG) copolymers. The in vivo studies revealed that LA-loaded NPs proved to be a promising system for curing glaucoma without inducing any side effects [15].Topical drug delivery is considered as the easiest method for ophthalmic drug delivery and has gained patient compliance over time. Once a drug is topically applied, due…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.